Igan on Rheumatology Digesthttps://rheumatologydigest.org/tags/igan/Recent content in Igan on Rheumatology DigestHugoen-usSun, 24 May 2026 06:00:00 +0530Telitacicept for IgA Nephropathy — Interim Analysis of a Phase 3 Trialhttps://rheumatologydigest.org/posts/telitacicept-igan-phase3/Sun, 24 May 2026 06:00:00 +0530https://rheumatologydigest.org/posts/telitacicept-igan-phase3/In the TELIGAN phase 3 trial, telitacicept — a dual BAFF/APRIL inhibitor already approved for SLE — reduced 24-hour proteinuria by 55% relative to placebo at 39 weeks in adults with IgA nephropathy, with eGFR remaining stable on treatment while declining on placebo.